Evidence map›Paper›PMID 30400982›Full record

ArticleArthritis research & therapy2018

Intrauterine fetal deaths related to antiphospholipid syndrome: a descriptive study of 65 women.

Mériem Belhocine, Laetitia Coutte, Nicolas Martin Silva, Nathalie Morel, Gaëlle Guettrot-Imbert, Romain Paule, Claire Le Jeunne, Micaela Fredi, Michel Dreyfus, Jean-Charles Piette and 6 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Arthritis research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 2 countries.

Mériem BelhocineAP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'île de France, 27 Rue du Faubourg Saint Jacques, 75014, Paris, France.
Laetitia CoutteAP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'île de France, 27 Rue du Faubourg Saint Jacques, 75014, Paris, France.
Nicolas Martin SilvaCaen University Hospital, Internal Medicine Department, Caen, France.
Nathalie MorelAP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'île de France, 27 Rue du Faubourg Saint Jacques, 75014, Paris, France.
Gaëlle Guettrot-ImbertAP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'île de France, 27 Rue du Faubourg Saint Jacques, 75014, Paris, France.
Romain PauleAP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'île de France, 27 Rue du Faubourg Saint Jacques, 75014, Paris, France.
Claire Le JeunneAP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'île de France, 27 Rue du Faubourg Saint Jacques, 75014, Paris, France.
Micaela FrediSpedali Civili di Brescia, Rheumatology and Clinical Immunology Department, Brescia, Italy.
Michel DreyfusCaen University Hospital, Gynecology and Obstetrics Department, Caen, France.
Jean-Charles PietteAP-HP, Pitié-Salpétrière University Hospital, Internal Medicine and Clinical Immunology Department, Centre de référence maladies auto-immunes et systémiques rares de l'île de France, Université Paris 6, Paris, France.
Odile Souchaud-DebouveriePoitiers University Hospital, Internal Medicine Department, Poitiers, France.
Catherine Deneux-TharauxINSERM U1153, Obstetrical, Perinatal and Paediatric Epidemiology (EPOPé research team), DHU Risks in Pregnancy, Université Paris Descartes, Paris, France.
Vassilis TsatsarisAP-HP, Cochin Hospital, Port-Royal maternity, Gynecology and Obstetrics Department, DHU Risks in Pregnancy, INSERM U1139, Paris, France.
Emmanuelle PannierAP-HP, Cochin Hospital, Port-Royal maternity, Gynecology and Obstetrics Department, DHU Risks in Pregnancy, INSERM U1139, Paris, France.
Véronique Le GuernAP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'île de France, 27 Rue du Faubourg Saint Jacques, 75014, Paris, France.
Nathalie Costedoat-ChalumeauAP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'île de France, 27 Rue du Faubourg Saint Jacques, 75014, Paris, France. nathalie.costedoat@gmail.com.
Hôpital Cochin · FRAssistance Publique – Hôpitaux de Paris · FRInserm · FRUniversité de Caen Normandie · FRAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITMaternité Port Royal · FRSorbonne Université · FRUniversité de Poitiers · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAlthough one of the three obstetric manifestations of antiphospholipid syndrome (APS) is intrauterine fetal death (IUFD), little is known about it in this context. We report the first large series of patients with APS and IUFD.

methodsWe retrospectively analyzed the history and clinical data of women at four French hospitals. All had (1) APS diagnosis (Sydney criteria) and (2) IUFD at or after 10 weeks of gestation (weeks) between 2000 and 2016.

resultsThe study included 65 women. Their median age at the index IUFD was 29 years (IQR 26-33); 38 (58%) were primigravidas. The index IUFD was the first APS clinical manifestation in 48 women (74%). Overall, 35% had a triple-positive antibody profile. IUFD occurred at a median gestational age of 24 weeks (IQR 18-27) and was associated with maternal obstetric complications in 16 women (25%), namely, preeclampsia (n = 12), hemolysis, elevated liver enzymes, and low platelet syndrome (HELLP) (n = 6), and/or placental abruption (n = 5). Half of the 50 women with available data had a small-for-gestational-age fetus. Overall, including during the follow-up period of 4 years (IQR 2-9), 28 women (43%) had at least one thrombosis, and 29% were diagnosed with systemic lupus erythematosus (SLE). Ultimately, 54 women (83%) had at least one live birth. Only one woman had three consecutive early miscarriages.

conclusionIUFD was most often the inaugural sign of APS. Of the APS classification criteria, IUFD, preeclampsia, and thromboses were common in this cohort, while the "3 consecutive early miscarriages" criterion was met only once. With treatment, most of the women successfully had at least one live birth.

Indexed as

AdultAntibodies, AntiphospholipidAntiphospholipid SyndromeFemaleFetal DeathFollow-Up StudiesFranceHumansPregnancyPregnancy ComplicationsRetrospective StudiesAntibodies, AntiphospholipidAntiphospholipid syndromeHELLPIntrauterine fetal deathLupusPreeclampsiaPregnancyThrombosis

Identifiers

PMID30400982
PMCPMC6235231
OpenAlexW2900183580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.